A number of large varieties cut off supply! Hospital one-time full-time fixed year-round use drug companies are worried about the end

Pharmaceutical Network June 15th, one south and one north, fancy staged drug "off supply" story"4 plus 7" collection, medical institutions become generous, a fixed amount of one year also pay the full amount, put in the former pharmaceutical companies that the music blossomed, but now face the supply does not come, limited supply but also be scolded the situationAt the other end, the government supports medical institutions are "economic", the price pressure is the lowest in the country, almost close to the country's 50% state, raw materials rose, pharmaceutical companies can not supply, received the investigation notice letterNational harvest half of the varieties, pharmacies can not get goods, medical institutions crazy, directly a booking enough for the whole year, resulting in enterprise production capacity pressure, limited supply and by public opinion pressure, Yunnan Province, part of the national varieties "off supply" the truth gradually surfacedHowever, in Liaoning, on the other side of China, there is another "cut-off": the price of raw materials has risen sharply, and the supply of "life-saving drugs" for heart surgery is insufficient01The Yunnan National Harvest varieties "off supply" behind therecently, Yunnan Province Medical Insurance Bureau issued on the nationaldrugcentralized procurement of Yunnan selected enterprises abnormal supply varieties table, the annex shows that there is a shortage of 8 varieties, including Entikawe, Atofastatin calcium The equality of benzene sulfonate ammonia chloride, involving the supply enterprises are Suzhou Dongrui, Xing'an Pharmaceutical, Changzhou Four Drugs, Yangzijiang Pharmaceutical Group Jiangsu Pharmaceuticals, National Pharmaceutical Group Rongsheng Pharmaceuticals, Hanyu Pharmaceuticals, Guangzhou Baiyunshan Tianxin Pharmaceuticals, Hunan Warner Pharmaceutical StakesIt is worth noting that the eight varieties are all concentrated and expanded varieties, and the total number of expansion varieties is only 25, close to a third of the proportion, the reasons behind it are worth exploringPhoto Source: Yunnan Medical Insurance Bureau
YunnanPharmaceuticalCo., Ltdis theof the distributionenterprises of these 8 varietiesPeople familiar with the company told E drug managers that the main factors are affected by three factors:is affected by the outbreak, including Hunan Warner PharmaceuticalS, Xing'an Pharmaceuticals, Dongrui Pharmaceuticals and other companies to resume production delaysSecond, the volume factor, many pharmaceutical companies will reserve a certain amount of supply space when accepting the offer, but now the situation is half a year in advance of the procurement of the volume of the whole yearIt has little impact on medical institutions, but it has a huge impact on production companies, such as Ubersatan, which is supplied by Hanyu Pharmaceuticals, and is experiencing a shortage of capacity"For example, the volume of procurement to the pharmaceutical company reported 5 million tablets, the enterprise to produce up to 6 million tablets, but now half a year needs 6 million tabletsThese capacity is not employees overtime can be done, is the need to increase the production line, and the line increase requires a series of complex procedures, so in the short term to fill these gaps is not realistic"The business people saidThird, from the "4 plus 7", many products are actually from the retail channels tohospitalback, because the hospital has become the price of these products "low-lying""As far as I know, more than half of the products, the first batch of second batch of products purchased in volume,pharmaciesare not available"After the reflux, there are some abnormal fluctuations in the amount of dosage in medical institutions, medical institutions may consider it normal, but for suppliers, the short time is not able to withstand such a sudden surge in demand." 　　"The supply was agreed upon at the time of the negotiation, can you choose not to supply the excess supply?" "
" from the public opinion, he has a choice? The above-mentioned person replied, "In fact, there are still a large number of hospitals that do not purchase products, these hospitals are responsible for some procurement indicators, and some of the original did not report excessive hospitals, products were robbed as soon as they arrived." "For example, the original box of 20 yuan, medical institutions to purchase 20,000 boxes need 400,000 yuan, a lump sum is not realistic." But now, a box of price reduction into 2 yuan, a purchase of 40,000 yuan, some medical institutions directly a full year 　　Now many provinces are based on this principle: as long as you have over-reported, or online procurement, are to collect prices, how much to how much "Of course, there are many industrial enterprises are also limited, the same by medical institutions and people scolded, but some enterprises because of the market control ability is strong and other factors, did not cause a great impact "
02 Liaoning 20
varieties of "cut off supply" , more than 3000 kilometers away from Yunnan, Liaoning, also announced a similar news 　　On June 11, the Liaoning Provincial Medical Insurance Bureau issued a summary of the non-agreed prices and regulations reported by medical institutions in January-May 2020, covering 15 injection strains such as atikain epinephrine injections, ammonia benzoic acid injections, and fish sulfate semen injections, and 5 other dosage forms Involved in enterprises have Yangzijiang Pharmaceutical Group subsidiary companies, Shanghai Xinyi, Jilin Yandong, Shuangyi Pharmaceuticals, Lisheng Pharmaceuticals, Yuekang Pharmaceuticals and other well-known pharmaceutical companies in order to find the reason for the cut-off, E drug manager first contacted one of the parties Yuekang Pharmaceuticals The company provides a fish-sulphate protein injection, it is known that fish sulphate is a deep-sea fish sperm protein is a isolation from the deep-sea fish stake of anti-heparin biologics, with the role of lifting anticoagulant to prevent haemorrhage, is a common drug in surgery, especially heart surgery, there is no alternative drug 　　Interestingly, the fish essence protein, known as the "life-saving drug", has a "cut-off" every five years In 2011 and 2016, there have been shortages of national scale, and this time Liaoning Province has announced a shortage of fish refined protein Yuekang Pharmaceuticals as the sole supplier, told E drug managers, the company's supply of fish refined protein is limited by the shortage of imported raw materials, affected by overseas outbreaks, either can not buy, or the price increase is very large, resulting in the previous negotiation price simply can not be implemented According to Yuekang, the price is still from four years ago with the Department of Drug Administration in the negotiations, the price is 45 yuan a box (5ml: 50mg x 5 pieces), while many other provinces are priced around 70 yuan, including the southern provinces 　　Recall 4 years ago, Liaoning Provincial Health and Planning Commission issued a drug shortage warning notice, including sulfuric acid fish protein and other 10 kinds of drugs, enterprise feedback can not be normal supply of the situation, for the price can not be timely, full supply of Kaifeng Pharmaceutical (Group) Co., Ltd., Shanghai First Biochemical Pharmaceutical Co., Ltd and other 7 production enterprises to give a warning 　　It is reported that the current domestic production of fish refined protein only Yuekang and Shanghai's first biochemical, the two production capacity is similar, Yuekang mainly for the north, the first biochemical mainly for the south 　　The rise in the shortage of raw materials is not a new problem An API company from Hunan said that this year, in addition to anti-viral API and imported API, the supply of other RAW drugs is relatively stable, including prices 　　It is worth noting that one south and one north of the "off supply" list, have appeared Yangzijiang Pharmaceutical Group Jiangsu subsidiary, a medium reason can be combined with analysis Tianjin Lisheng Pharmaceuticals also has two tablets included in the abnormal list, respectively, Malay acid chlorophenythronotablets and hydrochloroquine tablets, as of the reasons as of the release of the enterprise has not yet responded However, due to location reasons, Tianjin resumed production in the country is also relatively late 　　IN ADDITION, THE BILAND (ATIKAIN EPINEPHRINE INJECTION) PRODUCED BY FRANCE'S PRODUITS DENTAIRES PIERRE ROLLAND, ALTHOUGH IN JANUARY-MAY IN LIAONING SUPPLY PROBLEMS, BUT ON APRIL 10 IN SHENZHEN MEDICAL INSTITUTIONS It can be seen that the reason may not be a supply problem, but more a price problem 　　Pharmaceutical companies have analyzed that, like this kind of local short supply, the high probability may be the price, not the capacity problem